Update on Subclinical Hyperthyroidism



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2011 Apr 15;83(8):933-938.

  Patient information: See related handout on subclinical hyperthyroidism, written by the authors of this article.

Subclinical hyperthyroidism is defined by low or undetectable serum thyroid-stimulating hormone levels, with normal free thyroxine and total or free triiodothyronine levels. It can be caused by increased endogenous production of thyroid hormone (as in Graves disease or toxic nodular goiter), administration of thyroid hormone for treatment of malignant thyroid disease, or unintentional excessive thyroid hormone therapy. The rate of progression to overt hyperthyroidism is higher in persons who have suppressed thyroid-stimulating hormone levels compared with those who have low but detectable levels. Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation in older adults, and with decreased bone mineral density in postmenopausal women; however, the effectiveness of treatment in preventing these conditions is unknown. There is lesser-quality evidence suggesting an association between subclinical hyperthyroidism and other cardiovascular effects, including increased heart rate and left ventricular mass, and increased bone turnover markers. Possible associations between subclinical hyperthyroidism and quality of life parameters, cognition, and increased mortality rates are controversial. Prospective randomized controlled trials are needed to address the effects of early treatment on potential morbidities to help determine whether screening should be recommended in the asymptomatic general population.

Subclinical hyperthyroidism is defined by low or undetectable serum thyroid-stimulating hormone (TSH) levels, with normal free thyroxine (T4) and total or free triiodothyronine (T3) levels.1 Currently used third-generation assays are capable of detecting TSH at levels as low as 0.01 to 0.02 mIU per L. Subclinical hyperthyroidism can be divided into two categories: low but detectable TSH levels (0.1 to 0.4 mIU per L), and suppressed TSH levels (less than 0.1 mIU per L).1  Although there is compelling evidence that treatment of suppressed TSH is cost-effective, particularly in older adults, the importance of timely diagnosis and treatment of low but detectable TSH levels is controversial. The quality of evidence on the strength of association and benefits of treatment of subclinical hyperthyroidism is summarized in Table 1.1

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

There is conflicting evidence about the benefit of treating subclinical hyperthyroidism in adults older than 60 to 65 years who have cardiovascular risk factors.

C

1315

There is limited-quality evidence about the benefit of treating subclinical hyperthyroidism in postmenopausal women who have decreased bone mineral density.

B

25, 26

The U.S. Preventive Services Task Force concludes that the evidence is insufficient to recommend for or against routine screening for thyroid disease in adults.

C

31

The American Thyroid Association, the American Association of Clinical Endocrinologists, and The Endocrine Society recommend against routine screening for subclinical thyroid disease.

C

1


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, diseaseoriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

There is conflicting evidence about the benefit of treating subclinical hyperthyroidism in adults older than 60 to 65 years who have cardiovascular risk factors.

C

1315

There is limited-quality evidence about the benefit of treating subclinical hyperthyroidism in postmenopausal women who have decreased bone mineral density.

B

25, 26

The U.S. Preventive Services Task Force concludes that the evidence is insufficient to recommend for or against routine screening for thyroid disease in adults.

C

31

The American Thyroid Association, the American Association of Clinical Endocrinologists, and The Endocrine Society recommend against routine screening for subclinical thyroid disease.

C

1


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, diseaseoriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Table 1.

Subclinical Hyperthyroidism: Evidence of Adverse Effects and Treatment Benefits

Condition Strength of association Benefit of treatment
TSH 0.1 to 0.4 mIU per L TSH < 0.1 mIU per L TSH 0.1 to 0.4 mIU per L TSH < 0.1 mIU per L

Adverse cognitive effects

Unclear*

Unclear*

NA

NA

Adverse effects on quality of life

Unclear*

Unclear*

NA

Unclear*

Atrial fibrillation

Good-quality evidence

Good-quality evidence

NA

NA

Other adverse cardiovascular effects

Limited-quality evidence

Limited-quality evidence

NA

Limited-quality evidence

Increased bone fractures

NA

Unclear*

NA

NA

Increased bone turnover markers

Limited-quality evidence

Limited-quality evidence

NA

NA

Reduced bone mineral density (men or premenopausal women)

No association

No association

NA

NA

Reduced bone mineral density(postmenopausal women)

Unclear*

Good-quality evidence

Unclear*

Limited-quality evidence

Mortality

Unclear*

Unclear*

NA

NA

Progression to overt hyperthyroidism

Unclear*

Good-quality evidence

NA

NA


NA = no studies available; TSH = thyroid-stimulating hormone.

*—Data are conflicting or limited.

Information from reference 1.

Table 1.   Subclinical Hyperthyroidism: Evidence of Adverse Effects and Treatment Benefits

View Table

Table 1.

Subclinical Hyperthyroidism: Evidence of Adverse Effects and Treatment Benefits

Condition Strength of association Benefit of treatment
TSH 0.1 to 0.4 mIU per L TSH < 0.1 mIU per L TSH 0.1 to 0.4 mIU per L TSH < 0.1 mIU per L

Adverse cognitive effects

Unclear*

Unclear*

NA

NA

Adverse effects on quality of life

Unclear*

Unclear*

NA

Unclear*

Atrial fibrillation

Good-quality evidence

Good-quality evidence

NA

NA

Other adverse cardiovascular effects

Limited-quality evidence

Limited-quality evidence

NA

Limited-quality evidence

Increased bone fractures

NA

Unclear*

NA

NA

Increased bone turnover markers

Limited-quality evidence

Limited-quality evidence

NA

NA

Reduced bone mineral density (men or premenopausal women)

No association

No association

NA

NA

Reduced bone mineral density(postmenopausal women)

Unclear*

Good-quality evidence

Unclear*

Limited-quality evidence

Mortality

Unclear*

Unclear*

NA

NA

Progression to overt hyperthyroidism

Unclear*

Good-quality evidence

NA

NA


NA = no studies available; TSH = thyroid-stimulating hormone.

*—Data are conflicting or limited.

Information from reference 1.

Etiology and Prevalence

Subclinical hyperthyroidism may result from endogenous overproduction of thyroid hormone; it also may be exogenous as a result of intentional administration of thyroid hormone to suppress thyroid malignancy, or unintentional excessive hormone therapy in patients with hypothyroidism. Common causes of endogenous subclinical hyperthyroidism include Graves disease, autonomous functioning thyroid adenoma, and toxic multinodular goiter. Transient TSH suppression may occur during subacute, painless, or postpartum thyroiditis. There is an inverse correlation between population iodine intake and the prevalence of thyroid autonomy (thyroid tissue that functions without TSH), with a higher prevalence in iodinedeficient areas.2 The prevalence of subclinical hyperthyroidism varies among studies because of differences in defining the TSH level for subclinical hyperthyroidism, age of the study population, and use of thyroid hormone medication. The Third National Health and Nutrition Examination Survey evaluated thyroid antibodies and TSH and free T4 levels in persons older than 12 years who represented the geographic and ethnic distribution of the U.S. population.3 The prevalence of TSH levels less than 0.1 mIU per L was 0.7 percent, whereas 3.2 percent had levels less than 0.4 mIU per L.

The prevalence of subclinical hyperthyroidism has been reported to be as high as 15 percent in persons older than 70 years in iodine-deficient regions.4 The condition is most common in patients on thyroid hormone therapy, in whom the prevalence may be as high as 20 percent,5,6 particularly in those taking desiccated thyroid hormone.

Subclinical hyperthyroidism should be differentiated from other causes of low TSH levels that are not related to relative thyroid overactivity, such as the use of certain drugs (dopamine and glucocorticoids); nonthyroidal illness (euthyroid sick syndrome), pituitary causes (TSH deficiency); hypothalamic causes (thyrotropinreleasing hormone deficiency); and psychiatric conditions, especially affective disorders. T4 and T3 levels are generally lower in persons with these conditions, whereas patients with subclinical hyperthyroidism may have T4 and T3 levels in the mid to high reference range. A suggested diagnostic approach for patients with suspected subclinical hyperthyroidism is outlined in Figure 1.

Evaluation of Suspected Subclinical Hyperthyroidism

Figure 1.

Algorithm for the diagnosis of suspected subclinical hyperthyroidism. (TSH = thyroid-stimulating hormone; T4 = thyroxine; T3 = triiodothyronine.)

View Large

Evaluation of Suspected Subclinical Hyperthyroidism


Figure 1.

Algorithm for the diagnosis of suspected subclinical hyperthyroidism. (TSH = thyroid-stimulating hormone; T4 = thyroxine; T3 = triiodothyronine.)

Evaluation of Suspected Subclinical Hyperthyroidism


Figure 1.

Algorithm for the diagnosis of suspected subclinical hyperthyroidism. (TSH = thyroid-stimulating hormone; T4 = thyroxine; T3 = triiodothyronine.)

Natural History

Most patients with subclinical hyperthyroidism will not progress to overt hyperthyroidism. The factors that seem to affect the natural history include the degree of TSH suppression and the etiology. One study prospectively evaluated 102 women older than 60 years who had subclinical hyperthyroidism with TSH levels between 0.1 and 0.4 mIU per L.7 Of these women, three (2.9 percent) progressed to overt hyperthyroidism; four (3.9 percent) had TSH levels decrease to less than 0.1 mIU per L, with normal T3 and T4 levels; 24 (23.5 percent) had normalization of TSH levels; and 71 (69.5 percent) had TSH levels remain at 0.1 to 0.4 mIU per L over a median follow-up of 41 months. This represents a 1 percent progression to overt hyperthyroidism per year. The only predictor of progression was an initial TSH level less than 0.2 mIU per L. Women older than 65 years who had subclinical hyperthyroidism and TSH levels less than 0.1 mIU per L had a 27 percent progression to overt hyperthyroidism over two years,8 indicating that the chance of progression is higher in persons with TSH levels less than 0.1 mIU per L.

A retrospective analysis of the natural history of subclinical hyperthyroidism revealed that the course of disease is less predictable in patients with Graves disease than in those with toxic multinodular goiter.9 In Graves disease, patients experienced remission, progression, or no change after up to 36 months of follow-up, whereas most patients with subclinical hyperthyroidism caused by multinodular goiter tended to have stable thyroid function during the same follow-up period. Multinodular goiter is more common in iodinedeficient areas, and supplementation with iodine (including iodine-containing medications, such as amiodarone [Cordarone]) has been shown to precipitate subclinical hyperthyroidism.10

Cardiovascular and Mortality Risk

Cardiovascular effects of subclinical hyperthyroidism include an increase in average heart rate, increased risk of atrial arrhythmias, increased left ventricular mass, and reduced heart rate variability.11,12 Decreased heart rate variability on 24-hour Holter monitoring was noted in patients with subclinical and overt hyperthyroidism compared with control patients, which may predict an increased risk of subsequent cardiac events.12 In a retrospective, population-based study of adults older than 65 years on average, the prevalence of atrial fibrillation in persons with subclinical hyperthyroidism whose TSH levels were less than 0.4 mIU per L was 12.7 percent, compared with 2.3 percent in those with normal TSH levels. The age- and risk f a c tor – adjus t ed risk of atrial fibrillation is 2.8 in persons with subclinical hyperthyroidism compared with euthyroid control patients.13 Similarly, two large cohorts of adults older than 60 to 65 years found that subclinical hyperthyroidism is associated with an increased relative risk of developing atrial fibrillation over at least 10 years.14,15

Subclinical hyperthyroidism is associated with cardiovascular-specific and all-cause mortality, although the data are conflicting. A systematic review of prospective cohort studies that evaluated coronary heart disease and mortality in patients with subclinical hyperthyroidism (TSH levels less than 0.3 to 0.5 mIU per L) found a modest nonsignificant increase in risk.16 However, a meta-analysis involving different studies concluded that subclinical hyperthyroidism is associated with a 41 percent higher risk of all-cause mortality compared with euthyroid control patients, and that this risk increases with age.17 Recently, two population cohort studies from Germany and Brazil reached conflicting results regarding the association between low TSH levels and mortality risk.18,19 In an 8.5-year follow-up study in Pomerania, Germany, adjusted all-cause mortality was not increased in middle-aged patients with TSH levels less than 0.25 mIU per L.18 Conversely, Brazilian patients averaging 60 years of age who had TSH levels less than 0.45 mIU per L had a significant 20.3 percent increase in all-cause mortality risk over 7.5 years, but no increase in cardiovascular disease.19

Two studies evaluated the cardiovascular effects of treatment of low TSH levels with methimazole (Tapazole) 20 or radioactive iodine.21 The first study found that methimazole therapy in patients with suppressed TSH levels significantly decreased heart rate, atrial and ventricular premature beats, and left ventricular wall thickness six months after normalization of TSH levels, becoming similar to that of the control group.20 In another study, treatment with radioactive iodine in patients with subclinical hyperthyroidism (TSH levels less than 0.1 mIU per L) caused by multinodular goiter resulted in an 11 percent decrease in heart rate, 19 percent reduction in cardiac output, and a concomitant 30 percent increase in systemic vascular resistance after a mean follow-up period of 224 days after TSH normalization; however, this study lacked a euthyroid control group.21

Bone and Mineral Metabolism

Subclinical hyperthyroidism may reduce bone mineral density (BMD), particularly in cortical bone, although the impact is likely influenced by the duration of the disease, associated risk factors for bone loss, and degree of TSH suppression. Loss of bone mass with hyperthyroidism is a result of increased bone turnover caused by imbalance between bone reabsorption and formation,22 with a resulting decrease in BMD and increase in bone turnover markers. Although overt hyperthyroidism is associated with increased fracture risk, the studies are conflicting for patients with subclinical hyperthyroidism.

The impact of subclinical hyperthyroidism on BMD is most prominent in postmenopausal women. In a crosssectional study of women with endogenous subclinical hyperthyroidism (TSH levels of 0.01 to 0.1 mIU per L), postmenopausal women had significantly lower BMD at the level of the femur and lumbar regions, whereas premenopausal women had only a modest decrease in BMD in the femur area compared with matched euthyroid control patients.23 A meta-analysis of 12 studies also found an association between excessively decreased BMD in postmenopausal women, but not in premenopausal women or in men.24

There is evidence that suppressed TSH results in increased bone turnover markers, especially in postmenopausal women with exogenous subclinical hyperthyroidism. There are limited studies evaluating bone turnover markers in endogenous subclinical hyperthyroidism; however, the findings are similar. The evidence suggests bone benefit from treating postmenopausal women with subclinical hyperthyroidism. In one study, postmenopausal women with subclinical hyperthyroidism (TSH levels less than 0.2 mIU per L) due to multinodular goiter were treated with radioactive iodine ablation or were not treated, and were followed for two years.25 Treated patients had normal TSH levels and no significant change in lumbar and hip BMD, whereas the untreated patients with low TSH levels had a continued loss of bone mass of about 1 to 2 percent per year. Another study found a significant increase in BMD in persons with overt or subclinical hyperthyroidism (2.8 and 1.5 percent, respectively) after six months of normalization of thyroid function tests.26

Quality of Life and Cognitive Function

Patients with subclinical hyperthyroidism may experience increased signs and symptoms of adrenergic overactivity, particularly those younger than 50 years. Quality of life and specific signs and symptoms of excess thyroid hormone were assessed in 23 patients approximately 43 years of age (± nine years) who had TSH levels less than 0.3 mIU per L.11 Compared with age- and sex-matched euthyroid control patients, those with low TSH levels had a higher prevalence of palpitations, nervousness, tremor, heat intolerance, and sweating, and lower functional health and well-being. However, recent studies did not find a correlation between TSH levels and health-related quality of life scores in patients who had been treated for hyperthyroidism,27 or in a communitybased study of women that included patients with subclinical hyperthyroidism.28

The association between low TSH levels and dementia is controversial. The population-based prospective Rotterdam study evaluated a random sample of 1,846 patients older than 55 years, and found that TSH levels less than 0.4 mIU per L were associated with a 3.5-fold increased risk of dementia and Alzheimer disease during a two- to four-year follow-up.29 This risk was significantly higher in patients with both low TSH levels and positive antithyroid peroxidase antibodies, raising the possibility of an autoimmune mechanism. However, a recent study with the same population did not find an association between incident dementia or Alzheimer disease and TSH levels in a five-year follow-up.30 A population-based study in Italy revealed that patients older than 65 years who had TSH levels less than 0.46 mIU per L had lower Mini-Mental State Examination scores compared with euthyroid agematched control patients (22.61 ± 6.88 versus 24.72 ± 4.52, respectively [ P < .03]).31 In multivariate regression analysis, these patients had a more than twofold higher likelihood of cognitive impairment compared with agematched control patients.31 Further studies are needed to clarify whether there is a causal relationship between subclinical hyperthyroidism and cognitive decline, or whether the association between low TSH levels and dementia is confounded by a higher prevalence of nonthyroidal illness in older adults.

Screening Guidelines

There is no consensus regarding screening for subclinical hyperthyroidism in the general population. A criterion for recommending a screening test should be that detection and treatment of a disorder in asymptomatic persons would result in measurable improvement in health outcomes compared with persons who are not screened. The U.S. Preventive Services Task Force concluded in 2004 that there is good evidence that an undetectable TSH level is a risk factor for later development of atrial fibrillation, but there are no studies addressing whether treatment would prevent this complication.32 Similarly, a panel representing members of the American Thyroid Association, the American Association of Clinical Endocrinologists, and The Endocrine Society published the conclusions of their consensus conference evaluating the strength of the evidence for the management of subclinical thyroid disease with a recommendation against population-based screening for thyroid disease.1 However, it is also emphasized that recommendations derived from evidence-based medicine are population-based, and that physicians should use their best clinical judgment in the context of the recommendations for screening in individual patients.

The Authors

INES DONANGELO, MD, PhD, is an endocrinology fellow at Cedars-Sinai Medical Center, Los Angeles, Calif., and a clinical instructor at the David Geffen School of Medicine at the University of California, Los Angeles.

GLENN D. BRAUNSTEIN, MD, is the chair of medicine at Cedars-Sinai Medical Center.

Address correspondence to Glenn D. Braunstein, MD, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room #2119, Los Angeles, CA 90048 (e-mail: braunstein@cshs.org). Reprints are not available from the authors.

Author disclosure: Dr. Braunstein is a consultant in reproductive endocrinology for Abbott Diagnostics. This affiliation is not related to the topic of this article. Dr. Donangelo has nothing to disclose.

REFERENCES

1. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238.

2. Bülow Pedersen I, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab. 2002;87(10):4462–4469.

3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499.

4. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab. 1999;84(2):561–566.

5. De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. Br J Gen Pract. 1995;45(391):93–95.

6. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–534.

7. Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf). 2010;72(5):685–688.

8. Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf). 2008;68(3):491–492.

9. Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid. 2005;15(7):687–691.

10. Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid. 1998;8(1):83–100.

11. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function tin young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701–4705.

12. Petretta M, Bonaduce D, Spinelli L, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145(6):691–696.

13. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5):838–842.

14. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–1252.

15. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033–1041.

16. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832–845.

17. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008;159(3):329–341.

18. Ittermann T, Haring R, Sauer S, et al. Decreased serum TSH levels are not associated with mortality in the adult northeast German population. Eur J Endocrinol. 2010;162(3):579–585.

19. Sgarbi JA, Matsumura LK, Kasamatsu TS, Ferreira SR, Maciel RM. Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study. Eur J Endocrinol. 2010;162(3):569–577.

20. Sgarbi JA, Villaça FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88(4):1672–1677.

21. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145(4):391–396.

22. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115(2):151–162.

23. Rosario PW. Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arq Bras Endocrinol Metabol. 2008;52(9):1448–1451.

24. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a metaanalysis. J Clin Endocrinol Metab. 1996;81(12):4278–4289.

25. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf). 1998;48(3):285–290.

26. Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract. 2008;14(8):973–978.

27. Abraham-Nordling M, Wallin G, Lundell G, Törring O. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease. Eur J Endocrinol. 2007;156(2):173–179.

28. Bell RJ, Rivera-Woll L, Davison SL, Topliss DJ, Donath S, Davis SR. Wellbeing, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease - a community-based study. Clin Endocrinol (Oxf). 2007;66(4):548–556.

29. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf). 2000;53(6):733–737.

30. de Jong FJ, den Heijer T, Visser TJ. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2006;91(7):2569–2573.

31. Ceresini G, Lauretani F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57(1):89–93.

32. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(2):128–141.



Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article